Rodríguez Pizà, IgnasiVassena, RitaRichaud Patin, YvonneIzpisúa Belmonte, J. C.Raya Chamorro, ÁngelVeiga, AnnaBarrero Núñez, María JoséGonzález, Federico2011-07-272011-07-272010Rodríguez-Piza I, Richaud-Patin Y,Vassena R, González F, Barrero MJ, Veiga A. Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. Stem Cells. 2010;28(1):36-44. DOI: 10.1002/stem.2481066-5099http://hdl.handle.net/10230/12429The availability of induced pluripotent stem cells (iPSCs)/nhas created extraordinary opportunities for modeling and/nperhaps treating human disease. However, all reprogramming/nprotocols used to date involve the use of products of animal origin. Here, we set out to develop a protocol to generate and maintain human iPSC that would be entirely/ndevoid of xenobiotics. We first developed a xeno-free cell/nculture media that supported the long-term propagation of human embryonic stem cells (hESCs) to a similar extent as conventional media containing animal origin products or commercially available xeno-free medium. We also derived/nprimary cultures of human dermal fibroblasts under strict/nxeno-free conditions (XF-HFF), and we show that they can be used as both the cell source for iPSC generation as well as autologous feeder cells to support their growth. We also replaced other reagents of animal origin trypsin, gelatin, matrigel) with their recombinant equivalents. Finally, we used vesicular stomatitis virus G-pseudotyped retroviral particles expressing a polycistronic construct encoding Oct4, Sox2, Klf4, and GFP to reprogram XF-HFF cells under xeno-free conditions. A total of 10 xeno-free human/niPSC lines were generated, which could be continuously passaged in xeno-free conditions and aintained characteristics indistinguishable from hESCs, including colony/nmorphology and growth behavior, expression of pluripotency-/nassociated markers, and pluripotent differentiation/nability in vitro and in teratoma assays. Overall, the results/npresented here demonstrate that human iPSCs can be generated/nand maintained under strict xeno-free conditions and provide a path to good manufacturing practice (GMP) applicability that should facilitate the clinical translation of iPSC-based therapies.application/pdfeng© 2011 AlphaMed PressMedicina regenerativaCél·lules mare embrionàriesinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1002/stem.248Cell cultureClinical translationEmbryonic stem cellsiPS cellsGood manufacturing practiceinfo:eu-repo/semantics/openAccess